Has Prateek Gandiga, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,242 in general payments to Prateek Gandiga, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Prateek Gandiga, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Prateek Gandiga, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Prateek Gandiga, MD

Rheumatology · Atlanta, GANPI 1619193844

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,620 of the $2,242 with a category attached, or 72.2%. Johnson & Johnson accounts for 80.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,891 and has fallen 88.1% since, to $226 in 2025. That places this record below the midpoint for rheumatology clinicians in GA, where the typical reported total is $5,560.

$2,242in general payments, 2019–2025

Across 11 payments — averaging $203.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
AstraZeneca$130
Boston Scientific$126
Boehringer Ingelheim$90
Octapharma USA, Inc.$68
Aurinia Pharma U.S., Inc.$20

$212,093in research payments, 2019–2025

Across 5 payments — averaging $42,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$212K

What the payments were for

Consulting fees$1,62072%
Food & beverage$60327%
Education$201%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	3	$1,809
AstraZeneca	1	$130
Boston Scientific	2	$126
Boehringer Ingelheim	2	$90
Octapharma USA, Inc.	2	$68
Aurinia Pharma U.S., Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$1,766

How this compares

$2,242 in reported general payments places this provider in the 35th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia →

Medicare billing

Part B allowed, 2024

$51,298

Medicare patients

145

Services billed

370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	34	$709,943
GammaplexImmun Glob G(Igg)/Gly/Iga 0-50	14	$349,175
Humira(Cf) PenAdalimumab	29	$345,394
SimponiGolimumab	17	$246,334
Orencia ClickjectAbatacept	32	$192,188
Humira PenAdalimumab	27	$182,412
Gamunex-CImmune Globul G/Gly/Iga Avg 46	20	$113,346
Mycophenolate Mofetil	53	$15,360
RasuvoMethotrexate/Pf	12	$10,070
Hydroxychloroquine Sulfate	208	$8,310
Azathioprine	115	$5,774
Tacrolimus	17	$3,589
MethotrexateMethotrexate Sodium	181	$3,584
Duloxetine Hcl	97	$3,344
Leflunomide	29	$1,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonSimponi	$1,809	$246,33417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Atlanta

Gary MyersonAtlanta$1M
William WilsonAtlanta$344K
Paul SutejAtlanta$140K
Sung LimAtlanta$125K
Arezou KhosroshahiAtlanta$66K
Kimberley WilsonAtlanta$41K
John GoldmanAtlanta$33K
Wambui MachuaAtlanta$31K
Paula TanasaAtlanta$31K
Rattandeep SinghAtlanta$20K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →